Live from the NIH registry
Studies recruiting near Kennewick right now
Top 25 of 55 recruiting studies, sorted by proximity — each links to its official registry page
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: NRG Oncology
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
FAmily Engagement Strategy for Coordinated Specialty Care
Family Members, Implementation
N/A
Interventional 450 participants sought
Comprehensive Healthcare — Pasco, Washington (4.5 mi)
· Sponsor: Washington State University
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Phase 2
Interventional 44 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Phase 2
Interventional 46 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Multiple conditions
Phase 2
Interventional 314 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Phase 2
Interventional 84 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 247 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
Phase 3
Interventional 264 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
N/A
Interventional 535 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Phase 3
Interventional 303 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Breast Cancer
Phase 3
Interventional 420 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Hoffmann-La Roche
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: NRG Oncology
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Pancreatic Neoplasm
N/A
Observational 770 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
N/A
Observational 2,000 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma
Phase 3
Interventional 294 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Eastern Cooperative Oncology Group
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 3
Interventional 804 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Phase 2
Interventional 26 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Multiple conditions
N/A
Observational 2,900 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder
N/A
Observational 2,240 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Kadlec Clinic Hematology and Oncology — Kennewick, Washington (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
Central Line Associated Blood Stream Infections (CLABSI)
N/A
Interventional 17,800 participants sought
Kadlec Regional Medical Center — Richland, Washington (8.1 mi)
· Sponsor: Swedish Medical Center